de Azambuja, Evandro http://orcid.org/0000-0001-9501-4509
Ponde, Noam
Procter, Marion
Rastogi, Priya
Cecchini, Reena S.
Lambertini, Matteo
Ballman, Karla
Aspitia, Alvaro Moreno
Zardavas, Dimitrios
Roca, Lise
Gelber, Richard D.
Piccart-Gebhart, Martine
Suter, Thomas
Funding for this research was provided by:
National Cancer Institute (Financial Disclosures The NSABP B-31 Trial was supported by NCI grants: U10CA180868, -180822, UG1-189867, U24-196067.)
Article History
Received: 14 September 2019
Accepted: 19 September 2019
First Online: 11 October 2019
Compliance with ethical standards
:
: Evandro de Azambuja has received honoraria and advisory board from Roche/GNE and Seattle Genetics; travel grants from Roche/GNE and GSK/Novartis and research grants to his Institute: Roche/GNE; AstraZeneca, GSK/Novartis, Servier. Noam Pondé has received honoraria from AZ and Eli Lilly and travel grants from Eli Lilly and Novartis. Marion Procter has declared that her institution received funding from Roche in respect to the HERA and APHINITY trials. Matteo Lambertini has received honoraria from Theramex and consulting fee from TEVA. Pryia Rastogi has received travel and accommodations supported by Lilly, AZ, and GNE/Roche. Martine Piccart has been declared board Member (Scientific Board): Oncolytics, Radius; consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Periphagen, Pfizer, Roche, Seattle Genetics; research grants to her Institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. Thomas Suter has declared research support from Novartis and Amgen; consultant from Pfizer and advisory Board from Alnylam. Richard D Gelber declares that his institution receives support for his salary from Roche, AstraZeneca, Merck, Novartis, Ipsen, Celgene, Pfizer, and Ferring. Dimitrios Zardavas has declared employment from BMS. Karla V. Ballman has declared consulting or Advisory Role from ARIAD; Medtronic; Takeda; Agenus; Patents, Royalties, Other Intellectual Property: Prostate cancer signature patent (Inst); Expert Testimony—Janssen Oncology; Lilly. Lise Roca, Alvaro Moreno Aspitia, and Reena Cecchini have no conflict of interest to declare.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in each of the studies (HERA, NSABP B-31 (NRG Oncology) and NCCTG N9831 (Alliance)).